UCLTF fund drug development platform Canbex for the treatment of multiple sclerosis

Canbex was established to develop the VSN compound series, a drug development platform with potential applications in a wide range of therapeutic areas due to its mechanism of action. The lead molecule of the series, VSN16R, is in a Phase II trial for the treatment of spasticity in people with multiple sclerosis.

Related Content

We make UCL’s research physical and life sciences ideas happen.